[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] The hydrogel trial only included low/intermediate risk patients because of this theoretical risk. My understanding is some radiation oncologists feel comfortable doing it in high risk but in a community setting it's harder to say 'it's probably OK' without data.